Entering the gene therapy era

Y. H H Lien, Li-Wen Lai

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Gene therapy is a new modality with the potential for treating a variety of diseases, inherited or acquired. Although the initial clinical trials, particularly those for cystic fibrosis, have not been successful, the preliminary results of more recent studies of gene therapy for myocardial infarction are encouraging. New plasmids, viral and nonviral vectors, and applications are being developed at a rapid pace. A switch is now inserted in the plasmids so that the therapeutic gene can be turned on and off as needed. A chimeric RNA/DNA oligonucleotide has also been designed so that mutated genes can be converted to normal sequences. These and other novel approaches soon will propel the gene therapy industry into reality. Healthcare providers and educators need to be prepared for the coming of the gene therapy era.

Original languageEnglish (US)
Pages (from-to)718-721
Number of pages4
JournalJournal of the Formosan Medical Association
Volume98
Issue number11
StatePublished - 1999

Fingerprint

Genetic Therapy
Plasmids
Cystic Fibrosis
Oligonucleotides
Health Personnel
Genes
Industry
Myocardial Infarction
Clinical Trials
RNA
DNA
Therapeutics

Keywords

  • Gene therapy
  • Gene transfer
  • Inherited diseases

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Entering the gene therapy era. / Lien, Y. H H; Lai, Li-Wen.

In: Journal of the Formosan Medical Association, Vol. 98, No. 11, 1999, p. 718-721.

Research output: Contribution to journalArticle

Lien, Y. H H ; Lai, Li-Wen. / Entering the gene therapy era. In: Journal of the Formosan Medical Association. 1999 ; Vol. 98, No. 11. pp. 718-721.
@article{72597454728a4f51bf57231c92c8b282,
title = "Entering the gene therapy era",
abstract = "Gene therapy is a new modality with the potential for treating a variety of diseases, inherited or acquired. Although the initial clinical trials, particularly those for cystic fibrosis, have not been successful, the preliminary results of more recent studies of gene therapy for myocardial infarction are encouraging. New plasmids, viral and nonviral vectors, and applications are being developed at a rapid pace. A switch is now inserted in the plasmids so that the therapeutic gene can be turned on and off as needed. A chimeric RNA/DNA oligonucleotide has also been designed so that mutated genes can be converted to normal sequences. These and other novel approaches soon will propel the gene therapy industry into reality. Healthcare providers and educators need to be prepared for the coming of the gene therapy era.",
keywords = "Gene therapy, Gene transfer, Inherited diseases",
author = "Lien, {Y. H H} and Li-Wen Lai",
year = "1999",
language = "English (US)",
volume = "98",
pages = "718--721",
journal = "Journal of the Formosan Medical Association",
issn = "0929-6646",
publisher = "Excerpta Medica Asia Ltd.",
number = "11",

}

TY - JOUR

T1 - Entering the gene therapy era

AU - Lien, Y. H H

AU - Lai, Li-Wen

PY - 1999

Y1 - 1999

N2 - Gene therapy is a new modality with the potential for treating a variety of diseases, inherited or acquired. Although the initial clinical trials, particularly those for cystic fibrosis, have not been successful, the preliminary results of more recent studies of gene therapy for myocardial infarction are encouraging. New plasmids, viral and nonviral vectors, and applications are being developed at a rapid pace. A switch is now inserted in the plasmids so that the therapeutic gene can be turned on and off as needed. A chimeric RNA/DNA oligonucleotide has also been designed so that mutated genes can be converted to normal sequences. These and other novel approaches soon will propel the gene therapy industry into reality. Healthcare providers and educators need to be prepared for the coming of the gene therapy era.

AB - Gene therapy is a new modality with the potential for treating a variety of diseases, inherited or acquired. Although the initial clinical trials, particularly those for cystic fibrosis, have not been successful, the preliminary results of more recent studies of gene therapy for myocardial infarction are encouraging. New plasmids, viral and nonviral vectors, and applications are being developed at a rapid pace. A switch is now inserted in the plasmids so that the therapeutic gene can be turned on and off as needed. A chimeric RNA/DNA oligonucleotide has also been designed so that mutated genes can be converted to normal sequences. These and other novel approaches soon will propel the gene therapy industry into reality. Healthcare providers and educators need to be prepared for the coming of the gene therapy era.

KW - Gene therapy

KW - Gene transfer

KW - Inherited diseases

UR - http://www.scopus.com/inward/record.url?scp=0033376762&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033376762&partnerID=8YFLogxK

M3 - Article

C2 - 10705686

AN - SCOPUS:0033376762

VL - 98

SP - 718

EP - 721

JO - Journal of the Formosan Medical Association

JF - Journal of the Formosan Medical Association

SN - 0929-6646

IS - 11

ER -